---
title: "Allarity Therapeutics secures CLIA certification for in-house DRP testing lab"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291945556.md"
description: "Allarity Therapeutics has obtained a CLIA Certificate of Registration for its in-house laboratory in Denmark. This certification enables the company to conduct DRP biomarker testing for U.S. registration trials, supporting potential pivotal studies for stenoparib. By shifting testing in-house, Allarity aims to reduce reliance on external labs, decrease turnaround times, and lower long-term development costs."
datetime: "2026-07-07T14:01:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291945556.md)
  - [en](https://longbridge.com/en/news/291945556.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291945556.md)
---

# Allarity Therapeutics secures CLIA certification for in-house DRP testing lab

-   Allarity Therapeutics received a CLIA Certificate of Registration for its in-house laboratory in Denmark. \* Certification clears the regulatory requirement to run DRP biomarker testing for U.S. registration trials, supporting a potential pivotal stenoparib study. \* Move shifts testing in-house, cutting reliance on external labs, reducing turnaround times, lowering long-term development costs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md)

## Related News & Research

- [Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer](https://longbridge.com/en/news/296098241.md)
- [Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio | RVVTF Stock News](https://longbridge.com/en/news/296357987.md)
- [Ju Fu Tang Biotech files board, board committee member list with disclosure roles](https://longbridge.com/en/news/296095917.md)
- [BioNxt completes IMPD, moves toward first human bioequivalence trial for sublingual cladribine film in MS](https://longbridge.com/en/news/296314929.md)
- [Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses](https://longbridge.com/en/news/296405637.md)